23
Feb

Shares of Celldex Therapeutics shot up 20% this morning after the biotech announced that the FDA had provided its breakthrough therapy designation for rindopepimut (Rintega), an experimental drug for patients with EGFRvIII-positive glioblastoma.

…read more

Source: Celldex jumps after gaining an FDA ‘breakthrough’

    

0 No comments